Brief: Genocea Biosciences Reports U.S. FDA Placing GEN-011 IND On Clinical Hold

Genocea Biosciences

20/07/2020 13:38

July 20 (Reuters) - Genocea Biosciences Inc  GNCA.O :
    * GENOCEA BIOSCIENCES INC - PROVIDES CLINICAL UPDATE
    * GENOCEA BIOSCIENCES INC - ANNOUNCED UPDATES TO ITS
CLINICAL
PROGRAMS, NEOANTIGEN VACCINE GEN-009 AND NEOANTIGEN CELL
THERAPY, GEN-011
    * GENOCEA BIOSCIENCES INC - RECEIVED VERBAL NOTIFICATION FDA
THAT
AGENCY HAS COMPLETED ITS REVIEW OF COMPANY'S IND FOR GEN-011
    * GENOCEA BIOSCIENCES INC - FDA INFORMED GENOCEA THAT IT IS
PLACING IND ON CLINICAL HOLD UNTIL IT RECEIVES ADDITIONAL
INFORMATION
    * GENOCEA BIOSCIENCES - FOR GEN-009, WILL SHARE INITIAL
CLINICAL
DATA ON FIRST 5 PATIENTS FROM PART B OF ONGOING PHASE 1/2A
CLINICAL TRIAL ON JULY 30

Source text for Eikon:  ID:nGNX9g2cwD 
Further company coverage:  GNCA.O 

 ((Reuters.Briefs@thomsonreuters.com;))